CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study

Cecilia T Costiniuk, Joel Singer, Marc-André Langlois, Iva Kulic, Judy Needham, Ann Burchell, Mohammad-Ali Jenabian, Sharon Walmsley, Mario Ostrowski, Colin Kovacs, Darrell Tan, Marianne Harris, Mark Hull, Zabrina Brumme, Mark Brockman, Shari Margolese, Enrico Mandarino, Jonathan B Angel, Jean-Pierre Routy, Aslam H Anis, Curtis Cooper, Cecilia T Costiniuk, Joel Singer, Marc-André Langlois, Iva Kulic, Judy Needham, Ann Burchell, Mohammad-Ali Jenabian, Sharon Walmsley, Mario Ostrowski, Colin Kovacs, Darrell Tan, Marianne Harris, Mark Hull, Zabrina Brumme, Mark Brockman, Shari Margolese, Enrico Mandarino, Jonathan B Angel, Jean-Pierre Routy, Aslam H Anis, Curtis Cooper

Abstract

Introduction: Most existing vaccines require higher or additional doses or adjuvants to provide similar protection for people living with HIV (PLWH) compared with HIV-uninfected individuals. Additional research is necessary to inform COVID-19 vaccine use in PLWH.

Methods and analysis: This multicentred observational Canadian cohort study will enrol 400 PLWH aged >16 years from Montreal, Ottawa, Toronto and Vancouver. Subpopulations of PLWH of interest will include individuals: (1) >55 years of age; (2) with CD4 counts <350 cells/mm3; (3) with multimorbidity (>2 comorbidities) and (4) 'stable' or 'reference' PLWH (CD4 T cells >350 cells/mm3, suppressed viral load for >6 months and <1 comorbidity). Data for 1000 HIV-negative controls will be obtained via a parallel cohort study (Stop the Spread Ottawa), using similar time points and methods. Participants receiving >1 COVID-19 vaccine will attend five visits: prevaccination; 1 month following the first vaccine dose; and at 3, 6 and 12 months following the second vaccine dose. The primary end point will be the percentage of PLWH with COVID-19-specific antibodies at 6 months following the second vaccine dose. Humoral and cell-mediated immune responses, and the interplay between T cell phenotypes and inflammatory markers, will be described. Regression techniques will be used to compare COVID-19-specific immune responses to determine whether there are differences between the 'unstable' PLWH group (CD4 <350 cells/mm3), the stable PLWH cohort and the HIV-negative controls, adjusting for factors believed to be associated with immune response. Unadjusted analyses will reveal whether there are differences in driving factors associated with group membership.

Ethics and dissemination: Research ethics boards at all participating institutions have granted ethics approval for this study. Written informed consent will be obtained from all study participants prior to enrolment. The findings will inform the design of future COVID-19 clinical trials, dosing strategies aimed to improve immune responses and guideline development for PLWH.

Trial registration number: NCT04894448.

Keywords: COVID-19; HIV & AIDS; immunology; virology.

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Gazzola L, Tincati C, Bellistrì GM, et al. . The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009;48:328–37. 10.1086/695852
    1. Lerner AM, Eisinger RW, Fauci AS. Comorbidities in persons with HIV: the Lingering challenge. JAMA 2019. 10.1001/jama.2019.19775
    1. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012;205 Suppl 3:S375–82. 10.1093/infdis/jis200
    1. Serrano-Villar S, Sainz T, Lee SA, et al. . Hiv-Infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014;10:e1004078. 10.1371/journal.ppat.1004078
    1. Klein MB, Lu Y, DelBalso L, et al. . Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007;45:234–40. 10.1086/518986
    1. French N, Gordon SB, Mwalukomo T, et al. . A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362:812–22. 10.1056/NEJMoa0903029
    1. Glaser JB, Volpe S, Aguirre A, et al. . Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis 1991;164:761–4. 10.1093/infdis/164.4.761
    1. Wallace MR, Brandt CJ, Earhart KC, et al. . Safety and immunogenicity of an inactivated hepatitis a vaccine among HIV-infected subjects. Clin Infect Dis 2004;39:1207–13. 10.1086/424666
    1. Crum-Cianflone NF, Wilkins K, Lee AW, et al. . Long-Term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011;203:1815–23. 10.1093/infdis/jir180
    1. Kemper CA, Haubrich R, Frank I, et al. . Safety and immunogenicity of hepatitis a vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003;187:1327–31. 10.1086/374562
    1. Overton ET, Sungkanuparph S, Powderly WG, et al. . Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005;41:1045–8. 10.1086/433180
    1. El Chaer F, El Sahly HM. Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity. Am J Med 2019;132:437–46. 10.1016/j.amjmed.2018.12.011
    1. Tedaldi EM, Baker RK, Moorman AC, et al. . Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004;38:1478–84. 10.1086/420740
    1. Staprans SI, Hamilton BL, Follansbee SE, et al. . Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727–37. 10.1084/jem.182.6.1727
    1. Amoah S, Mishina M, Praphasiri P, et al. . Standard-Dose intradermal influenza vaccine elicits cellular immune responses similar to those of intramuscular vaccine in men with and those without HIV infection. J Infect Dis 2019;220:743–51. 10.1093/infdis/jiz205
    1. Kroon FP, van Dissel JT, de Jong JC, et al. . Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000;18:3040–9. 10.1016/S0264-410X(00)00079-7
    1. d'Arminio Monforte A, Bonnet F, Bucher HC, et al. . What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? perspectives from European HIV cohorts. HIV Med 2020;21 Suppl 2:3–16. 10.1111/hiv.12935
    1. Millett GA. New pathogen, same disparities: why COVID-19 and HIV remain prevalent in U.S. communities of colour and implications for ending the HIV epidemic. J Int AIDS Soc 2020;23:e25639. 10.1002/jia2.25639
    1. Weiser JK, Tie Y, Beer L, et al. . Racial/Ethnic and income disparities in the prevalence of comorbidities that are associated with risk for severe COVID-19 among adults receiving HIV care, United States, 2014-2019. J Acquir Immune Defic Syndr 2021;86:297–304. 10.1097/QAI.0000000000002592
    1. R. P . Have COVID-19 vaccines been tested in people with HIV? NAM AIDSMAP, 2021. Available: [Accessed 15 Jan 2021].
    1. Ramasamy MN, Minassian AM, Ewer KJ, et al. . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet 2020;396:1979–93. 10.1016/S0140-6736(20)32466-1
    1. COVID-19 vaccine (ChAdOx1 nCoV-19) trial in South African adults with and without HIV-infection. NIH us national library of medicine. . Available: [Accessed 6 May 2021].
    1. Clinical study protocol: a phase 3, randomized, stratified, Observer-Blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine in adults aged 18 years and older. ModernaTX, Inc. Available: [Accessed 5 Nov 2020].
    1. Clinical Study Protocol: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older. Janssen Vaccines & Prevention B.V. Available: [Accessed 5 Nov 2020].
    1. Shinde V, Bhikha S, Hoosain Z, et al. . Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021;384:1899–909. 10.1056/NEJMoa2103055
    1. Ruddy JA, Boyarsky BJ, Werbel WA. Safety and antibody response to the first dose of SARS-CoV-2 messenger RNA vaccine in persons with HIV. AIDS 2021;35.
    1. Polack FP, Thomas SJ, Kitchin N, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15. 10.1056/NEJMoa2034577
    1. Weiskopf D, Schmitz KS, Raadsen MP, et al. . Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol 2020;5. 10.1126/sciimmunol.abd2071. [Epub ahead of print: 26 06 2020].
    1. J DA Z, Pearce H, et al. . Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. BioRxiv 2020:20201101362319v1.
    1. Sewell HF, Agius RM, Kendrick D, et al. . Covid-19 vaccines: delivering protective immunity. BMJ 2020;371:m4838. 10.1136/bmj.m4838
    1. Deeks SG, Martin JN, Sinclair E, et al. . Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004;189:312–21. 10.1086/380098
    1. Deeks SG, Phillips AN. Hiv infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:a3172. 10.1136/bmj.a3172
    1. Peng X, Ouyang J, Isnard S, et al. . Sharing CD4+ T cell loss: when COVID-19 and HIV collide on immune system. Front Immunol 2020;11:596631. 10.3389/fimmu.2020.596631
    1. Jackson LA, Anderson EJ, Rouphael NG, et al. . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 2020;383:1920–31. 10.1056/NEJMoa2022483
    1. Pereira B, Xu X-N, Akbar AN. Targeting inflammation and Immunosenescence to improve vaccine responses in the elderly. Front Immunol 2020;11:583019. 10.3389/fimmu.2020.583019
    1. Wagner A, Garner-Spitzer E, Jasinska J, et al. . Age-Related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep 2018;8:9825. 10.1038/s41598-018-28111-8
    1. Wagner A, Weinberger B. Vaccines to prevent infectious diseases in the older population: immunological challenges and future perspectives. Front Immunol 2020;11:717. 10.3389/fimmu.2020.00717
    1. Braunstein SL, Lazar R, Wahnich A, et al. . COVID-19 infection among people with HIV in New York City: a population-level analysis of matched surveillance data. SSRN Journal 2020. 10.2139/ssrn.3675416
    1. Dandachi D, Geiger G, Montgomery MW, et al. . Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clin Infect Dis 2021;73:e1964-e1972. 10.1093/cid/ciaa1339
    1. Hoffmann C, Casado JL, Härter G, et al. . Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med 2021;22:372–8. 10.1111/hiv.13037
    1. Lu W, Mehraj V, Vyboh K, et al. . CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc 2015;18:20052. 10.7448/IAS.18.1.20052
    1. Nanditha NGA, Paiero A, Tafessu HM, et al. . Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study. BMJ Open 2021;11:e041734. 10.1136/bmjopen-2020-041734
    1. Roy Cardinal M-H, Durand M, Chartrand-Lefebvre C, et al. . Increased carotid artery wall stiffness and plaque prevalence in HIV infected patients measured with ultrasound elastography. Eur Radiol 2020;30:3178–87. 10.1007/s00330-020-06660-9
    1. Triplette M, Justice A, Attia EF, et al. . Markers of chronic obstructive pulmonary disease are associated with mortality in people living with HIV. AIDS 2018;32:487–93. 10.1097/QAD.0000000000001701
    1. Gallant J, Hsue PY, Shreay S, et al. . Comorbidities among US patients with prevalent HIV Infection-A trend analysis. J Infect Dis 2017;216:1525–33. 10.1093/infdis/jix518
    1. Richardson S, Hirsch JS, Narasimhan M, et al. . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. JAMA 2020;323:2052–9. 10.1001/jama.2020.6775
    1. Pfizer BioNTech a phase 1/2/3 placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-COV-2 RNA vaccine candidates against COVID-10 in healthy inviduals protocol number C4591001, 2021. Available:
    1. Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. AIDS Patient Care STDS 2014;28:397–410. 10.1089/apc.2014.0121
    1. Ding S, Laumaea A, Benlarbi M, et al. . Antibody binding to SARS-CoV-2 S glycoprotein correlates with but does not predict neutralization. Viruses 2020;12:1214. 10.3390/v12111214
    1. Beaudoin-Bussières G, Laumaea A, Anand SP, et al. . Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. mBio 2020;11. 10.1128/mBio.02590-20. [Epub ahead of print: 16 10 2020].
    1. Prévost J, Gasser R, Beaudoin-Bussières G, et al. . Cross-Sectional evaluation of humoral responses against SARS-CoV-2 spike. Cell Rep Med 2020;1:100126. 10.1016/j.xcrm.2020.100126
    1. Grifoni A, Weiskopf D, Ramirez SI, et al. . Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020;181:e1415:1489–501. 10.1016/j.cell.2020.05.015
    1. Perreault J, Tremblay T, Fournier M-J, et al. . Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood 2020;136:2588–91. 10.1182/blood.2020008367
    1. Rocheleau LLG, Fu K, Cote M. Consistent and high-frequency identification of an intra-sample genetic variant of SARS-CoV2 with elevated fusogeneic properties. Biorxiv. 10.1101/2020.12.03.409714
    1. Cao Y, Qiu Y, Tu G, et al. . Single-Cell RNA sequencing in immunology. Curr Genomics 2020;21:564–75. 10.2174/1389202921999201020203249
    1. Mehraj V, Ramendra R, Isnard S, et al. . Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection. Clin Infect Dis 2020;70:232–41. 10.1093/cid/ciz212
    1. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008;26:3551–5. 10.1016/j.vaccine.2008.04.054
    1. Cook IF. Sex differences in injection site reactions with human vaccines. Hum Vaccin 2009;5:441–9. 10.4161/hv.8476
    1. Saadat S, Rikhtegaran Tehrani Z, Logue J, et al. . Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA 2021;325:1467–9. 10.1001/jama.2021.3341
    1. Blain H, Tuaillon E, Gamon L, et al. . Spike antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose. JAMA 2021. 10.1001/jama.2021.6042. [Epub ahead of print: 15 Apr 2021].
    1. Wellcome sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak. Available: [Accessed 10 Mar 2021].
    1. Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, et al. . Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency. J Clin Immunol 2021;41:1146–53. 10.1007/s10875-021-01046-y
    1. Bajaj V, Gadi N, Spihlman AP, et al. . Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections? Front Physiol 2020;11:571416. 10.3389/fphys.2020.571416
    1. Gustafson CE, Kim C, Weyand CM, et al. . Influence of immune aging on vaccine responses. J Allergy Clin Immunol 2020;145:1309–21. 10.1016/j.jaci.2020.03.017
    1. Poonia B, Kottilil S. Immune correlates of COVID-19 control. Front Immunol 2020;11:569611. 10.3389/fimmu.2020.569611
    1. Walsh EE, Frenck RW, Falsey AR, et al. . Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439–50. 10.1056/NEJMoa2027906
    1. Wong C, Althoff K, Gange SJ. Identifying the appropriate comparison group for HIV-infected individuals. Curr Opin HIV AIDS 2014;9:379–85. 10.1097/COH.0000000000000063
    1. Helleberg M, Afzal S, Kronborg G, et al. . Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2013;56:727–34. 10.1093/cid/cis933
    1. Altice FL, Kamarulzaman A, Soriano VV, et al. . Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010;376:367–87. 10.1016/S0140-6736(10)60829-X
    1. Triant VA, Lee H, Hadigan C, et al. . Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506–12. 10.1210/jc.2006-2190

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren